Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older Adults With Sarcopenia (COQ10)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04999488
Recruitment Status : Not yet recruiting
First Posted : August 10, 2021
Last Update Posted : December 29, 2021
Sponsor:
Information provided by (Responsible Party):
AdventHealth Translational Research Institute

Brief Summary:
This study is being done to gather data on whether oral supplementation of CoQ10 is enriched in the blood and muscles in older adults with sarcopenia. This study involves 28 consecutive days of oral CoQ10 supplementation to explore changes in muscle strength, aerobic capacity and physical function with CoQ10 supplementation.

Condition or disease Intervention/treatment Phase
Sarcopenia Drug: BPM31510 Other: Placebo Early Phase 1

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 40 participants
Allocation: Randomized
Intervention Model: Single Group Assignment
Intervention Model Description: Randomized, parallel arm trial in which the supplementation with oral BPM 31510 or placebo will be blind.
Masking: None (Open Label)
Masking Description: Randomized, parallel arm trial in which the supplementation with oral BPM 31510 or placebo will be blind.
Primary Purpose: Basic Science
Official Title: Impact of Orally Administered BPM31510 on Mitochondrial Energetics in Older
Estimated Study Start Date : March 2022
Estimated Primary Completion Date : August 2022
Estimated Study Completion Date : August 2022

Arm Intervention/treatment
Placebo Comparator: Older adults with sarcopenia (placebo) Other: Placebo
A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.

Active Comparator: Older adults with sarcopenia (drug) Drug: BPM31510
A total of 3200 mg of BPM 31510 or placebo will be self-administered daily by subjects before the morning, afternoon, and evening meals, with no fewer than 4 and no more than 6 hours elapsed between doses during the daytime.




Primary Outcome Measures :
  1. Measurement of skeletal muscle [ Time Frame: Following 28 days of treatment ]
    We will evaluate changes in mitochondrial function (respiration) on permeabilized skeletal muscle fiber bundles obtained from biopsies of the vastus lateralis and blood draws, respectively. Blood and muscle biospecimens will also be obtained for multi-omics analysis.

  2. Measurement of platelet CoQ10 level [ Time Frame: Following 28 days of treatment ]
    We will evaluate changes in mitochondrial function (respiration) on cells (platelets) obtained from biopsies of the vastus lateralis and blood draws, respectively. Blood and muscle biospecimens will also be obtained for multi-omics analysis.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   65 Years to 90 Years   (Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Participant must be male or female, ages 65 through 90 years of age.
  2. Participant must be sedentary, defined as ≤ 1 structured intentional continuous exercise session (approximately 30 mins) per week.
  3. Participant must be sarcopenic, defined as having a skeletal muscle mass index (SMI) of <7.25 kg/m2 for males or <5.67 kg/m2 for females via DEXA scan.
  4. Participant states willingness to follow the protocol as described and will complete any forms needed throughout the study.
  5. Participant has voluntarily signed and dated an informed consent form, approved by an Institutional Review Board/Independent Ethics Committee, and provided Health Insurance Portability and Accountability Act authorization (HIPAA) or other privacy authorization prior to any participation in study.

Exclusion Criteria:

  1. Inability and/or unwillingness to comply with the protocol as written
  2. Participant has had a significant cardiovascular event (e.g., myocardial infarction, stroke) ≤ 6 months prior to screening visit; or stated history of congestive heart failure; or participant has evidence of cardiovascular disease assessed during the ECG at screening. In the event of a positive stress test, participants are referred to their primary care physician. If the electrocardiogram (ECG) is determined to be a false positive, participant may be allowed to participate in study after confirmatory records obtained.
  3. The presence of any condition which contraindicate moderate exercise and would result in the inability to comply with the protocol as written or would compromise participant safety or data integrity, will be considered on a case-by-case basis by the Principal investigator and the study physician.
  4. Participant is actively pursuing weight loss and/or lifestyle changes.
  5. History of gastrointestinal or intracranial hemorrhage.
  6. History of stroke or cerebrovascular accident.
  7. Participant has diabetes.
  8. Weight stable -no gain/loss by self-report of ≥ 10 lbs in 6 months prior to screening
  9. BMI 40.0 kg/m2
  10. Untreated or poorly controlled hypertension (SBP 150, DBP 95), or hypotension (SBP 100 DBP 60)
  11. Participant has untreated hyperthyroidism (TSH (0.5mIU/L) or untreated hypothyroidism (TSH 10mIU/L).
  12. Participant has current infection (requiring prescription antimicrobial or antiviral medication, or hospitalization), or corticosteroid treatment (with the exception of inhaled or topical steroids) in the last 3 months prior to screening visit.
  13. Participant is currently taking anti-inflammatory medication or has had anti-inflammatory medication within 1 week prior to screening (including over the counter formulations, e.g., Aleve, Motrin, ibuprofen, naproxen, low dose aspirin).
  14. Participant has had surgery requiring > 2 days of hospitalization in the last 1 month prior to screening visit.
  15. Participant has an active malignancy or autoimmune disease.
  16. Participant has current significantly impaired liver function in the opinion of the study Medical Investigator (mild asymptomatic fatty liver is acceptable), or hepatic enzyme tests are ≥ 2.5 times normal limit.
  17. Participant has a chronic, contagious, or infectious diseases, such as active tuberculosis, Hepatitis B or C, or HIV, per self-report.
  18. Participant currently has uncontrolled severe diarrhea, nausea or vomiting.
  19. Participant has an obstruction of the gastrointestinal tract, inflammatory bowel disease, short bowel syndrome or other forms of gastrointestinal disease such as stage III or above gastroesophageal reflux disease, gastroparesis, peptic ulcer disease, celiac disease, intestinal dysmotility, diverticulitis, ischemic colitis and bariatric surgery.
  20. Participant has a mini-Mental State Examination score < 21.
  21. Unable to participate in DXA assessments due to physical limitations of equipment tolerances (e.g., DXA 450-pound weight limit), claustrophobia, or based on Investigator's judgment at screening.
  22. Participant has a sensitivity or allergy to lidocaine.
  23. Presence of any condition that, in the opinion of the Investigator, compromises participant safety or data integrity or the participant's ability to complete the study.
  24. Participant has peripheral vascular disease.
  25. Participant has proteinuria defined as > 1+; approximately 30 mg/dl.
  26. Clinically significant abnormality on ECG

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04999488


Contacts
Layout table for location contacts
Contact: Recruitment Dept 407-303-7100 Fh.tri.recruitment@adventhealth.com

Locations
Layout table for location information
United States, Florida
AdventHealth Translational Research Institute
Orlando, Florida, United States, 32804
Sponsors and Collaborators
AdventHealth Translational Research Institute
Investigators
Layout table for investigator information
Principal Investigator: Paul Coen, PhD AdventHealth Translational Research Institute
Layout table for additonal information
Responsible Party: AdventHealth Translational Research Institute
ClinicalTrials.gov Identifier: NCT04999488    
Other Study ID Numbers: 1665113
First Posted: August 10, 2021    Key Record Dates
Last Update Posted: December 29, 2021
Last Verified: December 2021

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sarcopenia
Muscular Atrophy
Neuromuscular Manifestations
Neurologic Manifestations
Nervous System Diseases
Atrophy
Pathological Conditions, Anatomical